Destroys radicals which are normally produced within the cells and which are toxic to biological systems (PubMed:24140062). Catalyzes the oxidation of hydrogen sulfide (H2S) to sulfate, playing an important role in detoxifying H2S and limiting the accumulation of reactive sulfur species (RSS) such as persulfides and polysulfides (PubMed:36630448)
Homodimer; non-disulfide-linked (By similarity). Homodimerization may take place via the ditryptophan cross-link at Trp-33. Heterodimer with SOD1 (PubMed:31292775).
The heterodimer CCS:SOD1 interacts with SLC31A1; this heterotrimer is Cu(1+)-mediated and its maintenance is regulated through SOD1 activation (PubMed:31292775). Interacts with DAOA; the interaction is direct (PubMed:30037290)
A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates.
The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.
An autosomal recessive, neurologic disorder characterized by loss of motor abilities in the first year of life, after which severe, progressive spastic tetraparesis develops. Affected individuals have severe axial hypotonia, hyperekplexia, hypertonia, and myokymia, reflecting upper motor neuron involvement. Cognitive development may be affected.
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to SOD1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 30
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT05974579 | Amyotrophic Lateral Sclerosis | Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis | PHASE1 | ACTIVE_NOT_RECRUITING |
| NCT03449212 | Amyotrophic Lateral Sclerosis, Familial, Amyotrophic Lateral Sclerosis, Sporadic | SOD1 Kinetics Measurements in ALS Patients | N/A | SUSPENDED |
| NCT06556394 | Amyotrophic Lateral Sclerosis | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation | PHASE1 | RECRUITING |
| NCT03865420 | ALS | Amyotrophic Lateral Sclerosis (ALS) Families Project | N/A | RECRUITING |
| NCT01083667 | Familial Amyotrophic Lateral Sclerosis | SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) | PHASE1, PHASE2 | COMPLETED |
| NCT07077668 | ALS (Amyotrophic Lateral Sclerosis) | Extended Study of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation | EARLY_PHASE1 | NOT_YET_RECRUITING |
| NCT06100276 | Amyotrophic Lateral Sclerosis | Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT07223723 | Amyotrophic Lateral Sclerosis | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | PHASE4 | RECRUITING |
| NCT04744532 | Amyotrophic Lateral Sclerosis | iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study | PHASE1, PHASE2 | UNKNOWN |
| NCT00706147 | Amyotrophic Lateral Sclerosis | Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis | PHASE2, PHASE3 | COMPLETED |